Outcome, survival, and costs in patients undergoing intubation for carcinoma of the esophagus

In this prospective study a consec utive series of 70 patients undergoing insertion of a Wilson-Cook endoprosthesis for palliation of esophageal carcinoma was examined. The tube was inserted endoscopically using intravenous sedation and a pulsion technique. The patients had a mean (SEM) age of 70.7...

Full description

Saved in:
Bibliographic Details
Published inThe American journal of surgery Vol. 174; no. 3; pp. 316 - 319
Main Authors O'Hanlon, Deirdre M., Callanan, Keith, Karat, Daya, Crisp, William, Michael Griffin, S.
Format Journal Article
LanguageEnglish
Published New York, NY Elsevier Inc 01.09.1997
Elsevier
Elsevier Limited
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:In this prospective study a consec utive series of 70 patients undergoing insertion of a Wilson-Cook endoprosthesis for palliation of esophageal carcinoma was examined. The tube was inserted endoscopically using intravenous sedation and a pulsion technique. The patients had a mean (SEM) age of 70.7 (1.5) years and 44 (63%) were men. Two patients died in hospital and 2 died after discharge, giving a procedure-related mortality of 2.8% and a 30-day mortality of 5.7%. Nine patients experienced complications, giving a morbidity rate of 12.8% following the initial procedure. Twenty patients required a second or further procedure. The indications were tube migration in 22 cases, obstruction in 10, and fistula formation in 2 patients. Thirty-day mortality in this group was significantly greater than after a first procedure (7 patients, 20.1%; P < 0.05). The median survival following insertion of a Wilson-Cook endoprosthesis was 16 weeks. This study describes a safe, effective method for insertion of an endoprosthesis, with a low morbidity and mortality. The average cost for endoscopic insertion of a Wilson-Cook endoprosthesis in this unit is $1,600, and in view of the short median survival in this group of patients, the introduction of costly self-expanding stents is not warranted without demonstrable benefits in a controlled, prospective, randomized clinical trial.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0002-9610
1879-1883
DOI:10.1016/S0002-9610(97)00104-9